A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

March 23, 2026

Study Completion Date

April 6, 2026

Conditions
Obesity
Interventions
DRUG

CX11

CX11 tablets administered orally once daily (QD) with meals

OTHER

Placebo

Matching placebo tablets administered orally once daily (QD) with meals

Trial Locations (17)

33126

Angels Clinical Research Institute, Miami

33169

Oceanic Research Group, LLC, North Miami Beach

46383

Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS, Valparaiso

56001

Mankato Clinic - East Main Street - Javara - PPDS, Mankato

75057

Epic Clinical Research - Alliance Clinical - Lewisville, Lewisville

75230

Velocity Clinical Research - Dallas - PPDS, Dallas

78229

AES - DRS - Synexus Clinical Research US, Inc. - San Antonio, San Antonio

Flourish Research - San Antonio - PPDS, San Antonio

90301

310 Clinical Research - Alliance Clinical - Los Angeles, Inglewood

92120

Acclaim Clinical Research - Alliance Clinical - San Diego, San Diego

85020-4327

AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central, Phoenix

33122-1713

Angels Clinical Research Institute - Miami, Doral

32934-8172

AES - DRS - Optimal Research Florida - Melbourne, Melbourne

33014-2266

Palm Springs Community Health Center, Miami Lakes

31406-3928

Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS, Savannah

31792-6618

Privia Medical Group Georgia, LLC - Thomasville - Javara - PPDS, Thomasville

45246-2316

Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS, Cincinnati

Sponsors
All Listed Sponsors
lead

Corxel Pharmaceuticals

INDUSTRY